RxDoctor Payments Data

Samantha Padberg, APRN

Gerontology · Nashville, TNNPI 1609470624

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 30.2% of the total. Reporting peaked in 2022 at $498 and has fallen 97.0% since, to $15 in 2025.

$1,208in general payments, 2019–2025

Across 14 payments — averaging $86.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$365
  • Inspire Medical Systems, Inc.$168
  • Abiomed$167
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • AbbVie$100
  • Medtronic$99
  • plus $209 from 4 others

What the payments were for

  • Food & beverage$1,208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208 in reported general payments places this provider in the 80th percentile of 194 gerontology providers in Tennessee.

See all gerontology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,348
Medicare patients
24
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol33$48,835
Everolimus30$40,294
Repatha SureclickEvolocumab32$31,425
EliquisApixaban22$22,349
VascepaIcosapent Ethyl46$20,324
JardianceEmpagliflozin13$17,927
Sildenafil Citrate13$15,287
OzempicSemaglutide11$12,978
Sirolimus24$10,963
Tacrolimus73$10,645
Valganciclovir Hcl15$7,016
Mycophenolate Mofetil32$3,660
Omega-3 Acid Ethyl Esters30$2,383
Cyclosporine ModifiedCyclosporine, Modified11$1,959
Rosuvastatin Calcium159$1,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$365$48,83533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 194 gerontology providers in Tennessee.

Other gerontology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →